Abstract
The purpose of our study of synthetic inhibitors of thrombin was to find out novel compounds which inhibit thrombin greatly and selectively and to establish their structural features. In the process of the research, we recognized that synthetic inhibitors of thrombin should have additional properties, such that the acute and subacute toxicities are low, and that the Vd (volume of distribution) is small We considered that our thrombin inhibitor should meet these requirements, in perspective of using it in animal experiments and further even in clinical trials.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
S. Sherry, and W. Troll, The action of thrombin on synthetic substrates, J. Biol. Chem. 208: 95 (1954).
S. Okamoto, A. Hijikata, K. Ikezawa, E. Mori, R. Kikumoto, Y. Tamao, K. Ohkubo, T. Tezuka, and S. Tonomura, Structure-activity relationship in a series of synthetic thrombin inhibitors: No.205, No.407 and No.700, Blood and Vessel 11: 230 (1980).
M.J. Weinstein, and R.F. Doolittle, Differential specificities of thrombin, plasmin and trypsin with regard to synthetic and natural substrates and inhibitors, Biochim. Biophys. Acta. 258: 577 (1972).
S. Okamoto, K. Kinjo, A. Hijikata, R. Kikumoto, Y. Tamao, K. Ohkubo, and S. Tonomura, Thrombin inhibitors. 1. Ester derivatives of Na-(arylsulfonyl)-Larginine, J. Med. Chem. 23: 827 (1980).
R. Kikumoto, Y. Tamao, K. Ohkubo, T. Tezuka, S. Tonomura, S. Okamoto, Y. Funahara, and A. Hijikata, Thrombin inhibitors. 2. Amide derivatives of Na-substituted L-arginine, J. Med. Chem. 23: 830 (1980).
R. Kikumoto, Y. Tamao, K. Ohkuba, T. Tezuka, S. Tonomura, S. Okamoto, and A. Hijikata, Thrombin inhibitors. 3. Carboxyl-containing amide derivatives of Na-substituted L-arginine, J. Med. Chem. 23: 1293 (1980).
A. Hijikata, S. Okamoto, R. Kikumoto, and Y. Tamao, Kinetic studies on the selectivity of a synthetic thrombin-inhibitor using synthetic peptide substrates, Thromb. Haemostas. 42: 1039 (1979).
K. Oda, K. Ohtsu, Y. Tamao, R. Kikumoto, A. Hijikata, K. Kinjo, and S. Okamoto, Comparison of plasma levels and excretory routes between No.189 and No.407, potent thrombin inhibitors, Kobe J. Med. Sci. 26: 11 (1980).
S. Okamoto, A. Hijikata, R. Kikumoto, S. Tonomura, H. Hara, K. Ninomiya, A. Maruyama, M. Sugano, and Y. Tamao, Potent inhibition of thrombin by the newly synthesized arginine derivative No.805, The importance of stereo-structure of its hydrophobic carboxamide portion, Biochem. Biophys. Res. Commun. 101: 440 (1981).
R. Kikumoto, Y. Tamao, T. Tezuka, S. Tonomura, H. Hara, K. Ninomiya, A. Hijikata, and S. Okamoto, Selective inhibition of thrombin by (2R,4R)4-methyl-1-[N43-methyl-1, 2, 3, 4-tetrahydro-8-quinolinyl)sulfonyl]-Larginyl)1–2-piperidinecarboxylic acid, Biochemistry 23: 85 (1984).
B. Blombäck, M. Blombäck, P. Olsson, L. Svendsen, and G. Aberg, Synthetic peptides with anticoagulant and vasodilating activity, Scand. J. Clin. Lab. Invest. (Suppl.) 107: 59 (1969).
D.W. Banner, and P. Hadvary, Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors, J. Biol. Chem. 266: 20085 (1991).
Y. Tamao, T. Yamamoto, R. Kikumoto, H. Hara, J. Itoh, T. Hirata, K. Mineo, and S. Okamoto, Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo, Thromb. Haemostas. 56: 28 (1986).
H. Hara, Y. Tamao, and R. Kikumoto, Effect of argipidine (MD-805) on platelet function, Jpn. Pharmacol. Ther. (Supp1.5) 14: 875 (1986).
T. Kumada, and Y. Abiko, Comparative study on heparin and a synthetic thrombin inhibitor No.805 (MD-805) in experimental antithrombin III-deficient animals, Thromb. Res. 24: 285 (1981).
K. Fukutake, M. Tateyama, K. Amano, M. Ueda, and M. Fujimaki, Clinical pharmacology of argatroban - selective antithrombin agent - Comparative study with heparin. Cardioangiology 29: 190 (1991).
M. Iwaoto, T. Hara, H. Ogawa, and M. Tomikawa, Prophylactic effect of argipidine on development of lesions in rat peripheral arterial occlusion model, Jpn. Pharmacol. Ther. (Supp1.5) 14: 903 (1986).
T. Tanabe, Y. Mishima, K. Furukawa, S. Sakaguchi, K. Kamiya, S. Shionoya, T. Katsumura, and A. Kusaba, Clinical results of MD-805, antithrombin agent, on chronic arterial occlusion. A multicentre cooperative study, J. Clin. Thr. Med. 2: 1645 (1986).
T. Tanabe, K. Yasuda, M. Sakuma, H. Kubota, N. Kiyota, T. Imai, M. Kawabata, M. Matsuyama, M. Kawabata, S. Kuroshima, T. Shiono, T. Takahashi, Y. Marda, T. Kawakami, N. Kashimura, and S. Machida, Clinical experience of MD-805, antithrombin agent, on chronic arterial occlusion, J. Clin. Thr. Med. 2: 1635 (1986).
W.M. Feinberg, D.C. Bruck, M.E. Ring, and J.J. Corrigan Jr, Hemostatic markers in acute stroke, Stroke 20: 592 (1989).
K. lijima, Activated coagulation and fibrinolytic factors. Detection of protease/inhibitor complex, Jpn. J. Clin. Pathol. 36: 623 (1988).
T. Tanaka, N, Kawahata, L. Shin, K. Takasuka, Y. Nishimura, N. Yoshikawa, and T. Komatsu, Therapeutic effect of argipidine (MD-805), antithrombin agent, in the acute stage of cerebral thrombosis, J. Clin. Thr. Med. 3: 133 (1987).
M. Imiya, and T. Matsuo, In vitro and in vivo inhibition of platelet aggregation by argatroban (MD-805) in a patient with subacute cerebral thrombosis, Med. Consult. New Remed. 29: 911 (1992).
Y. Yonekawa, H. Handa, S. Okamoto, Y. Kamijo, Y. Oda, J. Ishikawa, H. Tsuda, Y. Shimizu, M. Satoh, T. Yamagami, I. Yano, Y. Horikawa, and E. Tsuda, Treatment of cerebral infarction in the acute stage with synthetic antithrombin MD -805: Clinical study among multiple institutions, Arch. Jpn. Chir. 55: 711 (1986).
S. Kobayashi, M. Kitani, S. Yamaguchi, T. Suzuki, K. Okada, and T. Tsunematsu, Effects of an antithrombotic agent (MD-805) on progressing cerebral thrombosis, Thromb. Res. 53: 305 (1989).
K. Nakamura, Y. Hatano, and K. Mori, Thrombin-induced vasoconstriction in isolated cerebral arteries and the influence of a synthetic thrombin inhibitor, Thromb. Res. 40: 715 (1985).
I. Maruyama, Synthetic anticoagulant, Jpn. J. Clin. Hematol. 31: 776 (1990).
D.C. Gulba, M. Barthels, G-H. Reil, and P.R. Lichtlen, Thrombin/antithrombin-III complex level as early indicator of reocclusion after successful thrombolysis, Lancet 9: 97 (1988).
J. Owen, K.D. Friedman, B.A. Grossman, C. Wilkins, A.D. Berke, and E.R. Powers, Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity, Blood 72: 616 (1988).
I-K. Jang, H.K. Gold, R.C. Leinbach, J.T. Fallon, and D. Collen, In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tossie-type plasminogen activator, Circulation Res. 67: 1552 (1990).
J. Schnieder, Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis, Thromb. Res. 64: 677 (1991).
S. Okamoto, and A. Hijikata, Drug design VI. In: Rational approach to proteinase inhibitors, E.J. Ariens ed. Academic Press, New York, pp. 143 (1975).
A. Hijikata-Okunomiya, S. Okamoto, Y. Tamao, and R. Kikumoto, Na-Dansyl-Larginine 4-phenylpiperidine amide, J. Biol. Chem. 263: 11269 (1988).
K. Wanaka, S. Okamoto, A. Okunomiya, M. Bohgaki, T. Naito, and Y. Okada, Trial to analyse the substrate-multiplicity of plasmin by using a novel synthetic inhibitor; with reference to amidolysis, fibrino(geno)lysis and bradykinin formation, Blood and Vessel 19: 368 (1988).
S. Okamoto, K. Wanaka, U. Okamoto, Y. Okada, N. Horie, and A. HijikataOkunomiya, Further studies on a newly synthetized active centre-directed plasmin inhibitor, Thromb. Haemostas. 65: 886 (1991).
S. Okamoto, N. Hone, K. Wanaka, U. Okamoto, M. Bohgaki, and A. HijikataOkunomiya, A novel synthetic potent plasmin-inhibitor inhibits tumor growth in Sarcoma-180 bearing mice, Thromb. Haemostas. 62: 40 (1989).
H. Fritz, and G. Wunderer, Biochemistry and application of aprotinin, the kallikrein inhibitor from bovine organs, Drug Res. 33: 479 (1983).
S. Okamoto, U. Okamoto, K. Wanaka, A. Hijikata-Okunomiya, M. Bohgaki, T. Naito, N. Horie, and Y. Okada, Kinins V (part B), in: Highly selective synthetic inhibitors with regard to plasma kallikrein activities, K. Abe et al. eds. Plenum Publishing Co., New York, pp. 29 (1989).
K. Wanaka, S. Okamoto, M. Bohgaki, A. Hijikata-Okunomiya, T. Naito, and Y. Okada, Effect of a highly selective plasma kallikrein synthetic inhibitor on contact activation relating to kinin generation, coagulation and fibrinolysis, Thromb. Res. 57: 889 (1990).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Okamoto, S., Wanaka, K., Hijikata-Okunomiya, A. (1993). In Vitro and In Vivo Properties of Synthetic Inhibitors of Thrombin: Recent Advances. In: Claeson, G., Scully, M.F., Kakkar, V.V., Deadman, J. (eds) The Design of Synthetic Inhibitors of Thrombin. Advances in Experimental Medicine and Biology, vol 340. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-2418-6_11
Download citation
DOI: https://doi.org/10.1007/978-1-4899-2418-6_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-2420-9
Online ISBN: 978-1-4899-2418-6
eBook Packages: Springer Book Archive